New nomenclature codes for stereotactic radiotherapy introduced in Belgium

27

May 2020

In April 2020, the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) introduced four new nomenclature codes for stereotactic radiotherapy (Belgian Monitor of April 27, 2020). Physicians also must register data on provided stereotactic radiotherapy series in the specific module of Cancer Registry Foundation.

New services belong to a category 4-bis of the INAMI nomenclature of health services for radiotherapy (article 18 §1 and article 19).

  • 444636-444640 Fixed fees for a series of stereotactic radiotherapy in a patient who meets the criteria in category 4bis, with primary tumors (except brain tumors)
  • 444651-444662 Fixed fees for a series of stereotactic radiotherapy in a patient who meets the criteria in category 4bis, with oligometastases (except brain metastases)
  • 444673-444684 Fixed fees for a series of stereotactic radiotherapy in a patient who meets the criteria in category 4bis, with malignant brain tumors and brain metastases
  • 444695-444706 Fixed fees for a series of stereotactic radiotherapy in a patient who meets the criteria in category 4bis, with non-malignant brain tumors and arteriovenous malformations (AVM)

Each of these services is remunerated at K 2000 (actual tariff is € 2,581.73)

The reimbursement conditions include registration data in the Cancer Registry Foundation. Personal data will be kept for 30 years after the patients' death. The purposes of this register are:

  • Quality control and monitoring of the costs of the care provided
  • Long-term prospective monitoring of mortality, recurrences and secondary cancers in order to assess and adapt the national policies

A multidisciplinary recommendation for this radiotherapy technique is required prior to each treatment series. It is a complex external irradiation with at least 6 Gy per fraction, which allows affecting the lesion with high precision.

The location of the irradiated lesion can be intracerebral or extracerebral. Stereotaxic radiotherapy to treat extracerebral lesions - primary tumors and - oligometastatic lesions (maximum of five lesions)

A maximum number of services that can be applied to one patient:

  • Three series of stereotactic radiotherapy for a patient, per 12 months and per organ
  • In total six times per 12 months for the whole body (including the brain)

Only one series of treatments can be invoiced per brain treatment procedure regardless of the number of lesions.

See the full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more

07

Mar 2022

On February 08, 2022, the Reimbursement Commission of the Social Security Institution released an updated version of the Healthcare Implementation Communique. The main changes relate to the increase in reimbursement fees of services and medical devices by approximately 35-75%.

Read more